451 related articles for article (PubMed ID: 30283733)
1. Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion.
Dong P; Xiong Y; Yue J; Hanley SJB; Watari H
Front Oncol; 2018; 8():386. PubMed ID: 30283733
[TBL] [Abstract][Full Text] [Related]
2. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
Jiang Y; Zhan H
Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
[TBL] [Abstract][Full Text] [Related]
3. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion.
Hsu JM; Xia W; Hsu YH; Chan LC; Yu WH; Cha JH; Chen CT; Liao HW; Kuo CW; Khoo KH; Hsu JL; Li CW; Lim SO; Chang SS; Chen YC; Ren GX; Hung MC
Nat Commun; 2018 May; 9(1):1908. PubMed ID: 29765039
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung.
Kim S; Koh J; Kim MY; Kwon D; Go H; Kim YA; Jeon YK; Chung DH
Hum Pathol; 2016 Dec; 58():7-14. PubMed ID: 27473266
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway.
Shen M; Xu Z; Xu W; Jiang K; Zhang F; Ding Q; Xu Z; Chen Y
J Exp Clin Cancer Res; 2019 Apr; 38(1):149. PubMed ID: 30961670
[TBL] [Abstract][Full Text] [Related]
6. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression.
Chen L; Gibbons DL; Goswami S; Cortez MA; Ahn YH; Byers LA; Zhang X; Yi X; Dwyer D; Lin W; Diao L; Wang J; Roybal J; Patel M; Ungewiss C; Peng D; Antonia S; Mediavilla-Varela M; Robertson G; Suraokar M; Welsh JW; Erez B; Wistuba II; Chen L; Peng D; Wang S; Ullrich SE; Heymach JV; Kurie JM; Qin FX
Nat Commun; 2014 Oct; 5():5241. PubMed ID: 25348003
[TBL] [Abstract][Full Text] [Related]
7. Bidirectional crosstalk between epithelial-mesenchymal plasticity and IFN
Burger GA; Nesenberend DN; Lems CM; Hille SC; Beltman JB
R Soc Open Sci; 2022 Nov; 9(11):220186. PubMed ID: 36397970
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation.
Almozyan S; Colak D; Mansour F; Alaiya A; Al-Harazi O; Qattan A; Al-Mohanna F; Al-Alwan M; Ghebeh H
Int J Cancer; 2017 Oct; 141(7):1402-1412. PubMed ID: 28614911
[TBL] [Abstract][Full Text] [Related]
9. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells.
Alsuliman A; Colak D; Al-Harazi O; Fitwi H; Tulbah A; Al-Tweigeri T; Al-Alwan M; Ghebeh H
Mol Cancer; 2015 Aug; 14():149. PubMed ID: 26245467
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 Expression in Human Breast Cancer Stem Cells Is Epigenetically Regulated through Posttranslational Histone Modifications.
Darvin P; Sasidharan Nair V; Elkord E
J Oncol; 2019; 2019():3958908. PubMed ID: 30915120
[TBL] [Abstract][Full Text] [Related]
11. ALDH3A1 Overexpression in Melanoma and Lung Tumors Drives Cancer Stem Cell Expansion, Impairing Immune Surveillance through Enhanced PD-L1 Output.
Terzuoli E; Bellan C; Aversa S; Ciccone V; Morbidelli L; Giachetti A; Donnini S; Ziche M
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31817719
[TBL] [Abstract][Full Text] [Related]
12. The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200.
Noman MZ; Janji B; Abdou A; Hasmim M; Terry S; Tan TZ; Mami-Chouaib F; Thiery JP; Chouaib S
Oncoimmunology; 2017; 6(1):e1263412. PubMed ID: 28197390
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma.
Asgarova A; Asgarov K; Godet Y; Peixoto P; Nadaradjane A; Boyer-Guittaut M; Galaine J; Guenat D; Mougey V; Perrard J; Pallandre JR; Bouard A; Balland J; Tirole C; Adotevi O; Hendrick E; Herfs M; Cartron PF; Borg C; Hervouet E
Oncoimmunology; 2018; 7(5):e1423170. PubMed ID: 29721376
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of PD-L1 expression in breast cancer cells through the formation of 3D multicellular cancer aggregates under different chemical and mechanical conditions.
Azadi S; Aboulkheyr Es H; Razavi Bazaz S; Thiery JP; Asadnia M; Ebrahimi Warkiani M
Biochim Biophys Acta Mol Cell Res; 2019 Dec; 1866(12):118526. PubMed ID: 31398408
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 regulation by SDH5 via β-catenin/ZEB1 signaling.
Tuo Z; Zong Y; Li J; Xiao G; Zhang F; Li G; Wang S; Lv Y; Xia J; Liu J
Oncoimmunology; 2019; 8(12):1655361. PubMed ID: 31741753
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-β induced epithelial mesenchymal transition in non-small cell lung cancer.
Funaki S; Shintani Y; Kawamura T; Kanzaki R; Minami M; Okumura M
Oncol Rep; 2017 Oct; 38(4):2277-2284. PubMed ID: 28849209
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation.
Qiu XY; Hu DX; Chen WQ; Chen RQ; Qian SR; Li CY; Li YJ; Xiong XX; Liu D; Pan F; Yu SB; Chen XQ
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1754-1769. PubMed ID: 29510196
[TBL] [Abstract][Full Text] [Related]
18. Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin β4/SNAI1/SIRT3 signaling pathway.
Wang S; Li J; Xie J; Liu F; Duan Y; Wu Y; Huang S; He X; Wang Z; Wu X
Oncogene; 2018 Jul; 37(30):4164-4180. PubMed ID: 29706653
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer.
Manjunath Y; Upparahalli SV; Avella DM; Deroche CB; Kimchi ET; Staveley-O'Carroll KF; Smith CJ; Li G; Kaifi JT
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31212653
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma.
Ock CY; Kim S; Keam B; Kim M; Kim TM; Kim JH; Jeon YK; Lee JS; Kwon SK; Hah JH; Kwon TK; Kim DW; Wu HG; Sung MW; Heo DS
Oncotarget; 2016 Mar; 7(13):15901-14. PubMed ID: 26893364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
